TriSalus Life Sciences to Participate in Upcoming September Investor Conferences

News > Health News

Audio By Carbonatix

7:00 AM on Thursday, August 28

The Associated Press

WESTMINSTER, Colo.--(BUSINESS WIRE)--Aug 28, 2025--

TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the following investor conferences in September:

Cantor Global Healthcare Conference 2025 in New York, NY
Management will participate in one-on-one meetings and participate in a fireside chat on Friday, September 5, at 9:35 a.m. ET. Click here for a link to the live webcast.

Lake Street Capital Markets 9th Annual Best Ideas Growth Conference in New York, NY
Management will participate in one-on-one meetings on Thursday, September 11.

A webcast replay of the fireside chat will be available for 90 days following the presentation in the Events section of the TriSalus Investor website at www.investors.trisaluslifesci.com.

About TriSalus Life Sciences
TriSalus Life Sciences® is an oncology focused medical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company’s two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD) approach to deliver a range of therapeutics: the TriNav® Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. The PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes. Nelitolimod, the Company’s investigational immunotherapeutic candidate, is designed to treat the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. The Company is in the final stages of data completion for a number of phase 1 clinical trials and will begin exploring partnership opportunities for development. In partnership with leading cancer centers across the country – and by leveraging deep immuno-oncology expertise and inventive technology development – TriSalus is committed to advancing innovation that improves outcomes for patients. Learn more at trisaluslifesci.com and follow us on X (formerly Twitter) and LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250828511190/en/

CONTACT: For Media Inquiries:

Jeremy Feffer, Managing Director

LifeSci Advisors

917.749.1494

[email protected] Investor Inquiries:

David Patience

Chief Financial Officer

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA NEW YORK COLORADO

INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL ONCOLOGY HEALTH FDA CLINICAL TRIALS

SOURCE: TriSalus Life Sciences